---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005424"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:03:50.105210+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atea reports $454.7M cash, plans global Phase 3 HCV program starting Q1 2025

## Summary
- Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024; cash runway into 2028.
- Phase 2 study met primary endpoints: 98% SVR12 in per-protocol population, 95% in efficacy evaluable (n=256).
- Global Phase 3 program for bemnifosbuvir + ruzasvir expected to initiate in Q1 2025; two open-label trials.
- End-of-Phase 2 meeting with FDA scheduled January 2025 to discuss Phase 3 program design.
- Company estimates global HCV market ~$3B annual net sales; regimen has potential best-in-class profile.

## SEC filing metadata
- accession: 0001193125-25-005424
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312525005424/0001193125-25-005424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312525005424/d924755d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005424
- JSON: https://secwatch.observer/filing/0001193125-25-005424.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.